Nervgen Pharma (NGEN) Total Current Liabilities (2024 - 2026)
Nervgen Pharma (NGEN) posted quarterly Total Current Liabilities of $11.1 million for Q1 2026, down 21.55% quarter-over-quarter from $14.2 million in Q4 2025.
Nervgen Pharma (NGEN) Total Current Liabilities (2024 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Total Current Liabilities for 3 consecutive years, with $11.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities changed N/A year-over-year to $11.1 million; the TTM figure through Mar 2026 stood at $11.1 million (changed N/A YoY), while the FY2025 annual figure was $14.2 million, up 16.95% from the prior year.
- Total Current Liabilities slipped to $11.1 million in Q1 2026 per NGEN's latest filing, from $14.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $14.2 million in Q4 2025 and bottomed at $11.1 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $12.5 million across 3 years, with a median of $12.1 million in 2024.
- On a YoY basis, Total Current Liabilities climbed as much as 16.95% in 2025 and fell as far as 16.95% in 2025.
- Nervgen Pharma's Total Current Liabilities stood at $12.1 million in 2024, then gained by 16.95% to $14.2 million in 2025, then decreased by 21.55% to $11.1 million in 2026.
- Business Quant data shows NGEN's Total Current Liabilities at $11.1 million in Q1 2026, $14.2 million in Q4 2025, and $12.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Nervgen Pharma | 161.78 Mn | 161.78 Mn | - | 52.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.10 Mn |
| Dec 31, 2025 | 14.15 Mn |
| Dec 31, 2024 | 12.10 Mn |